|
PSCI-24-106-MASTER |
Myelomatch, Master Screening And Reassessment Protocol (MSRP) For Tier Advancement In The NCI Myelomatch Clinical Trials |
|
PSCI-24-114 |
A Phase II Study Of Tailored Adjuvant Therapy In Pole-Mutated And P53- Wildtype/NSMP Early-Stage Endometrial Cancer (Rainbow Blue & Taper) |
|
PSCI-24-117 |
ARAR2221 A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC) |
|
PSCI-24-120 |
Phase II Trial of Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma BCC022 |
|
PSCI-24-123 |
Body Image and Sexual Functioning in Patients Undergoing Treatment for Cancer/Pre-cancer of the Vulva |
|
PSCI-24-126 |
A Phase III Trial Of Perioperative Versus Adjuvant Chemotherapy For Resectable Pancreatic Cancer |
|
PSCI-24-127 |
EXActDNA-003: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease (NSABP B-64) |
|
PSCI-24-139 |
NRG-BN013:Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases |
|
PSCI-25-003 |
EXActDNA-003: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease (NSABP B-64) |
|
PSCI-25-016 |
ACCL1931: A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy |
